KR

Krebs Biochemicals and Industries LtdNSE KREBSBIO Stock Report

Last reporting period 31 Mar, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.018

Micro

Exchange

XNSE - National Stock Exchange Of India

KREBSBIO.NS Stock Analysis

KR

Uncovered

Krebs Biochemicals and Industries Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-25/100

Low score

Market cap $B

0.018

Dividend yield

Shares outstanding

21.561 B

Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana and currently employs 210 full-time employees. The firm develops commercially viable biotech processes for application in medicine, agriculture and industry. The company is also engaged in chemical synthesis, fermentation and enzymatic technologies. The company manufactures various products, such as Androstenedione for use as steroid intermediate, and Lovastatin and Simvastatin for anti-cholesterol. The company also undertakes contract manufacturing for pharmaceutical and multinational companies and developing products for sale in global markets. The company has also products in the pilot or research and development stages, which include Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan and Phenylephrine. The company has two manufacturing facilities, one is located at Regadichelaka, Nellore District, and another one located at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.

View Section: Eyestock Rating